PAC 113

Drug Profile

PAC 113

Alternative Names: P 113L; PAC-113; PAC-113 Mouth Rinse

Latest Information Update: 22 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Demegen
  • Developer Demegen; General Biologicals Corporation; Pacgen Life Science Corporation
  • Class Antibacterials; Antifungals; Peptide antibiotics; Peptides
  • Mechanism of Action Cell membrane permeability enhancers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Candidiasis
  • Discontinued Gingivitis; Mucositis

Most Recent Events

  • 22 Jul 2016 Phase-II clinical trials in Candidiasis in Taiwan (PO) before July 2016
  • 24 Jan 2014 Pacgen Life Science enter into a sublicensing agreement with General Biological Corporation for PAC 113 for any oral condition (excluding transitional skin-mucous membrane areas) and also for vaginal, dermatological and ophthalmic conditions
  • 30 Apr 2012 Pacgen Biopharmaceuticals is now called Pacgen Life Science Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top